Vinge has represented the international private equity firm Cinven and Danish life science investment company Novo Holdings in their sale of Envirotainer Holding AB to EQT X Fund and Mubadala Investment Company, at an enterprise value of about EUR 2.8 billion. Vinge was supported by Clifford Chance.

Envirotainer develops, manufactures and leases active temperature-controlled containers, used primarily for air freighting biopharma products. The company was founded in 1985 in Stockholm and today its R&D, production and headquarters are based in the Stockholm region. With a global presence with about 375 employees in 20 countries and a fleet of about 6,500 containers, Envirotainer is the market leader in air transportation of temperature sensitive pharmaceuticals.

The Vinge team primarily consisted of Christina Kokko, Samra Baytar, Vilhelm Rondahl, Gustav Persson and Ida Redander (M&A), Victoria Gunnerek, Trine Osen Bergqvist and Ebba Thoms (EU, Competition & Regulatory), Linn Adelwald (Banking & finance), Isabell Nielsen and Sam Fakhraie Ardekani (Corporate Commercial), Sara Strandberg, Veronika Garemark, Emil Lindvall and Tove Tullberg (Employment & Corporate Crime), Kristoffer Larson (Real Estate), Axel Lennartsson and Rebecca Målquist (IP), Nicklas Thorgerzon (GDPR), Martin Boström (IT), Johan Cederblad and Lina Österberg (Permits & Environment), Viktoria Owetz Leyva, Christoffer Widström and Sara Dahlros Sköld (VDR).

Related

Vinge has advised Oncopeptides in connection with a directed share issue

Vinge has advised Oncopeptides in connection with a directed share issue, whereby Oncopeptides raises proceeds of SEK 100 million.
October 16, 2026

Vinge advises KGAL on its divestment of a Nordic wind portfolio to Enordic Evergreen

Vinge has advised KGAL on the divestment of a Nordic onshore wind portfolio to Enordic Evergreen.
October 14, 2026

Vinge has advised Orexo in connection with its rights issue

Vinge has advised Orexo AB (publ) in connection with a partially guaranteed rights issue of approximately SEK 250 million before transaction costs, subject to approval by an extraordinary general meeting.
October 09, 2026